Eli Lilly agreed to acquire privately held Calytrix Bio for up to $1.5 billion in cash, including an undisclosed upfront payment and additional clinical and regulatory milestones. Calytrix is developing a preclinical antibody targeting mutated calreticulin (CALR), a disease-associated driver in certain myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis. The experimental treatment is intended to target disease-driving cells while sparing healthy blood-forming cells, but has not yet entered human trials. The acquisition follows Lilly's earlier purchase of Ajax Therapeutics and expands its hematology strategy beyond its established metabolic portfolio.
Reuters
Why it matters strategically
Lilly is acquiring a mechanism and development opportunity before human proof of concept.
The headline transaction value therefore needs to be distinguished from the upfront consideration and the probability-weighted value of contingent payments.